Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Infection
Published in: Infection 6/2012

01-12-2012 | Case Report

Four cases of possible human infections with Delftia lacustris

Authors: S. Y. Shin, J. Y. Choi, K. S. Ko

Published in: Infection | Issue 6/2012

Login to get access

Abstract

We report four cases of possible human infections with Delftia lacustris. D. lacustris isolates, which were isolated from blood cultures and bile fluid of patients with underlying diseases such as empyema, renal injury, hepatocellular carcinoma, and renal infarction, were identified using 16S rRNA gene sequencing and biochemical tests. Four D. lacustris isolates did not show the same antimicrobial susceptibility profiles and enterobacterial repetitive intergenic consensus–polymerase chain reaction (ERIC-PCR) patterns, indicating their non-clonality.
Literature
1.
Jørgensen NOG, Brandt KK, Nybroe O, Hansen M. Delftia lacustris sp. nov., a peptidoglycan-degrading bacterium from fresh water, and emended description of Delftia tsuruhatensis as a peptidoglycan-degrading bacterium. Int J Syst Evol Microbiol. 2009;59:2195–9.PubMedCrossRef
2.
Chen WM, Lin YS, Sheu DS, Sheu SY. Delftia litopenaei sp. nov., a poly-β-hydroxybutyrate-accumulating bacterium isolated from a freshwater shrimp culture pond. Int J Syst Evol Microbiol. 2011. In press.
3.
Kawamura I, Yagi T, Hatakeyama K, Ohkura T, Ohkusu K, Takahashi Y, Kojima S, Hasegawa Y. Recurrent vascular catheter-related bacteremia caused by Delftia acidovorans with different antimicrobial susceptibility profiles. J Infect Chemother. 2011;17:111–3.PubMedCrossRef
4.
Preiswerk B, Ullrich S, Speich R, Bloemberg GV, Hombach M. Human infection with Delftia tsuruhatensis isolated from a central venous catheter. J Med Microbiol. 2011;60:246–8.PubMedCrossRef
5.
Shigematsu T, Yumihara K, Ueda Y, Numaguchi M, Morimura S, Kida K. Delftia tsuruhatensis sp. nov., a terephthalate-assimilating bacterium isolated from activated sludge. Int J Syst Evol Microbiol. 2003;53:1479–83.PubMedCrossRef
6.
Al Masalma M, Armougom F, Scheld WM, Dufour H, Roche PH, Drancourt M, Raoult D. The expansion of the microbiological spectrum of brain abscesses with use of multiple 16S ribosomal DNA sequencing. Clin Infect Dis. 2009;48:1169–78.PubMedCrossRef
7.
Chun J, Lee JH, Jung Y, Kim M, Kim S, Kim BK, Lim YW. EzTaxon: a web-based tool for the identification of prokaryotes based on 16S ribosomal RNA gene sequences. Int J Syst Evol Microbiol. 2007;57:2259–61.PubMedCrossRef
8.
Silbert S, Pfaller MA, Hollis RJ, Barth AL, Sader HS. Evaluation of three molecular typing techniques for nonfermentative Gram-negative bacilli. Infect Control Hosp Epidemiol. 2004;25:847–51.PubMedCrossRef
9.
Clinical and Laboratory Standards Institute (CLSI). Performance standards for antimicrobial susceptibility testing; twenty-first informational supplement; M100-S21. Wayne: CLSI; 2011.
10.
Wen A, Fegan M, Hayward C, Chakraborty S, Sly LI. Phylogenetic relationships among members of the Comamonadaceae, and description of Delftia acidovorans (den Dooren de Jong 1926 and Tamaoka et al. 1987) gen. nov., comb. nov. Int J Syst Bacteriol. 1999;49:567–76.PubMedCrossRef
11.
Lee SM, Kim MK, Lee JL, Wee WR, Lee JH. Experience of Comamonas acidovorans keratitis with delayed onset and treatment response in immunocompromised cornea. Korean J Ophthalmol. 2008;22:49–52.PubMedCrossRef
Metadata
Title
Four cases of possible human infections with Delftia lacustris
Authors
S. Y. Shin
J. Y. Choi
K. S. Ko
Publication date
01-12-2012
Publisher
Springer-Verlag
Published in
Infection / Issue 6/2012
Print ISSN: 0300-8126
Electronic ISSN: 1439-0973
DOI
https://doi.org/10.1007/s15010-012-0339-1

Other articles of this Issue 6/2012

Infection 6/2012 Go to the issue

Review

Review of intravenous immunoglobulin replacement therapy trials for primary humoral immunodeficiency patients

Brief Report

Human metapneumovirus infection after allogeneic hematopoietic stem cell transplantation

Correspondence

Reply to Dr. Rashmi Ranjan Das on the question, “Should procalcitonin be used as a routine biomarker of bacterial infection?”

Editorial

Infections are a global issue: Infection addresses global issues

Clinical and Epidemiological Study

Intestinal colonisation and blood stream infections due to vancomycin-resistant enterococci (VRE) and extended-spectrum beta-lactamase-producing Enterobacteriaceae (ESBLE) in patients with haematological and oncological malignancies

Case Report

Rare pediatric rhino-orbital infection caused by Saksenaea vasiformis
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits